Stress and rapid changes in mood are common conditions causing an increasing burden on individuals and their families. They are assumed to be the result of a complex constellation of vulnerability and risk factors. These include familial genetic and environmental factors, individual neurobiological aspects (e.g., brain circuitry/networks, stress reactivity, inflammation, metabolic and hormonal factors, cognitive-emotional dysregulation, and social-behavioral factors (e.g. physical activity ).
Hormones such as ghrelin and leptin regulate appetite and the metabolic state and, as a result, mood. They also modulate the brain’s reward system and our cognitive control. Moreover, there are known associations between these hormones and/or the resulting metabolic states and inflammatory markers which are also severely impaired at both ends of the weight spectrum and in conditions such as the metabolic syndrome . At the same time, the risk for affective dysregulation and/or mood changes is increased in individuals with these conditions. In depression research, there is evidence suggesting the existence of an immuno-metabolic subtype of depression, characterized by metabolic dysregulation similar to that seen in metabolic syndrome or (pre-)diabetes.
Since metabolic syndrome and type 2 diabetes predominantly affect older individuals, German federal states with aging populations, such as Saxony, face significant challenges regarding healthcare systems and people's quality of life.
As part of the International Research Training Group “Risks and Pathomechanisms of Affective Disorders” (IRTG 2773), our research focuses on the relationship between metabolic and inflammatory markers, and lifestyle in people affected by changes in mood. In our current SELS project, we study this relationship in individuals with metabolic alterations (e.g., prediabetes or diabetes) using questionnaires, an experimental psychology paradigm, and blood samples. Additionally, in the SELS project, we implement a smartphone-based lifestyle intervention aimed at increasing daily physical activity, as the metabolic and affective alterations described above can partly be compensated through physical activity—although the underlying mechanisms remain unclear.
Before, during, and after the lifestyle intervention, wearable activity sensors record physiological data throughout daily life, providing insights into behaviors such as sitting, physical activity, or lying down. Simultaneously, regular measurements of sleep and mood are conducted over an extended period via smartphones. This research method, known as Ecological Momentary Assessment (EMA), has the advantage of closely reflecting daily life happenings and capturing fluctuations and changes.
By combining these versatile research methods, we aim to examine the extent to which the relationship between biological parameters and markers of changing moods is influenced by a change in metabolic and inflammatory markers induced by a lifestyle intervention.
Contact persons:
Collaborators:
Professor Nikolaos Perakakis, MD., Head of Department for Metabolic Vascular Medicine Head of University Study Center for Metabolic Diseases, University Hospital Dresden
Prof. Dr. Stefan R. Bornstein Director of the Medical Clinic and Polyclinic III and the Center for Internal Medicine, University Hospital Dresden
Prof. Dr. med. Peter E.H. Schwarz, Medical Clinic & Polyclinic III, University Hospital Dresden
Prof. Dr. Carmine M. Pariante, Professor of Biological Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London
Dr. Alessandra Borsini, Institute of Psychiatry, Psychology and Neuroscience, King's College London
Prof. Dr. med. Dr. rer. nat. Michael Bauer, Clinic and Polyclinic for Psychiatry and Psychotherapy at the University Hospital Dresden.
Prof. Dr. med. Andrea Pfennig, Clinic and Polyclinic for Psychiatry and Psychotherapy, University Hospital Dresden
Jun.-Prof. Dr. rer. nat. Julia Martini, Junior Professor for Psychiatric Diagnostics and Intervention, Clinic and Polyclinic for Psychiatry and Psychotherapy, University Hospital Dresden
PD Dr. rer. nat. David Poitz, Head of Molecular Diagnostics, Allergy & Immunodiagnostics, Institute for Clinical Chemistry and Laboratory Medicine
References:
Al-Khatib Y, Akhtar MA, Kanawati MA, Mucheke R, Mahfouz M, Al-Nufoury M. Depression and Metabolic Syndrome: A Narrative Review. Cureus. 2022 Feb 12;14(2):e22153. doi: 10.7759/cureus.22153. PMID: 35308733; PMCID: PMC8920832.
Arora S, Anubhuti. Role of neuropeptides in appetite regulation and obesity--a review. Neuropeptides. 2006 Dec;40(6):375-401. doi: 10.1016/j.npep.2006.07.001. Epub 2006 Aug 28. PMID: 16935329.
Bailey AP, Hetrick SE, Rosenbaum S, Purcell R, Parker AG. Treating depression with physical activity in adolescents and young adults: a systematic review and meta-analysis of randomised controlled trials. Psychological Medicine. 2018;48(7):1068-1083. doi:10.1017/S0033291717002653.
Belvederi Murri M, Prestia D, Mondelli V, Pariante C, Patti S, Olivieri B, Arzani C, Masotti M, Respino M, Antonioli M, Vassallo L, Serafini G, Perna G, Pompili M, Amore M. The HPA axis in bipolar disorder: Systematic review and meta-analysis. Psychoneuroendocrinology. 2016 Jan;63:327-42. doi: 10.1016/j.psyneuen.2015.10.014. Epub 2015 Oct 21. PMID: 26547798.
Bernardoni F, Bernhardt N, Pooseh S, King JA, Geisler D, Ritschel F, Boehm I, Seidel M, Roessner V, Smolka MN, Ehrlich S. Metabolic state and value-based decision-making in acute and recovered female patients with anorexia nervosa. J Psychiatry Neurosci. 2020 Jul 1;45(4):253-261. doi: 10.1503/jpn.190031. PMID: 32129584; PMCID: PMC7828930.
de Jong, S., Diniz, M.J.A., Saloma, A. et al. Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder. Commun Biol 1, 163 (2018). https://doi.org/10.1038/s42003-018-0155-y
Dulubova I, Yamaguchi T, Gao Y, Min SW, Huryeva I, Südhof TC, Rizo J. How Tlg2p/syntaxin 16 'snares' Vps45. EMBO J. 2002 Jul 15;21(14):3620-31. doi: 10.1093/emboj/cdf381. PMID: 12110575; PMCID: PMC126126.
Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: A systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019 Oct;81:24-40. doi: 10.1016/j.bbi.2019.06.015. Epub 2019 Jun 10. PMID: 31195092.
Ehrlich S, Burghardt R, Schneider N, Broecker-Preuss M, Weiss D, Merle JV, Craciun EM, Pfeiffer E, Mann K, Lehmkuhl U, Hebebrand J. The role of leptin and cortisol in hyperactivity in patients with acute and weight-recovered anorexia nervosa. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jun 15;33(4):658-62. doi: 10.1016/j.pnpbp.2009.03.007. Epub 2009 Mar 16. PMID: 19296912.
Fürtjes S, Seidel M, King JA, Biemann R, Roessner V, Ehrlich S. Rumination in anorexia nervosa: Cognitive-affective and neuroendocrinological aspects. Behav Res Ther. 2018 Dec;111:92-98. doi: 10.1016/j.brat.2018.10.001. Epub 2018 Oct 2. PMID: 30396110.
Hering, A., Westphal, M., Gerken, A. et al. Improving assessment of lesions in longitudinal CT scans: a bi-institutional reader study on an AI-assisted registration and volumetric segmentation workflow. Int J CARS 19, 1689–1697 (2024). https://doi.org/10.1007/s11548-024-03181-4
Hibar, D., Westlye, L., Doan, N. et al. Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. Mol Psychiatry 23, 932–942 (2018). https://doi.org/10.1038/mp.2017.73
Hibar, D., Westlye, L., van Erp, T. et al. Subcortical volumetric abnormalities in bipolar disorder. Mol Psychiatry 21, 1710–1716 (2016). https://doi.org/10.1038/mp.2015.227
Iob, E., Kirschbaum, C. & Steptoe, A. Persistent depressive symptoms, HPA-axis hyperactivity, and inflammation: the role of cognitive-affective and somatic symptoms. Mol Psychiatry 25, 1130–1140 (2020). https://doi.org/10.1038/s41380-019-0501-6
Jaganathan R, Ravindran R, Dhanasekaran S. Emerging Role of Adipocytokines in Type 2 Diabetes as Mediators of Insulin Resistance and Cardiovascular Disease. Can J Diabetes. 2018 Aug;42(4):446-456.e1. doi: 10.1016/j.jcjd.2017.10.040. Epub 2017 Dec 8. PMID: 29229313.
Kanske, P., Heissler, J., Schönfelder, S., Bongers, A., Wessa, M. How to Regulate Emotion? Neural Networks for Reappraisal and Distraction, Cerebral Cortex, Volume 21, Issue 6, June 2011, Pages 1379–1388, https://doi.org/10.1093/cercor/bhq216
Kokkeler KJE, Voshaar RCO, Rhebergen D, van den Brink RHS, Spijker J, Marijnissen RM. Frailty measures in immuno-metabolic subtypes of late-life depression; A two-year prospective study. Arch Gerontol Geriatr. 2022 Mar-Apr;99:104603. doi: 10.1016/j.archger.2021.104603. Epub 2021 Dec 1. PMID: 34896798.
Lin Z, Feng W, Liu Y, Ma C, Arefan D, Zhou D, Cheng X, Yu J, Gao L, Du L, You H, Zhu J, Zhu D, Wu S, Qu S. Machine Learning to Identify Metabolic Subtypes of Obesity: A Multi-Center Study. Front Endocrinol (Lausanne). 2021 Jul 14;12:713592. doi: 10.3389/fendo.2021.713592. PMID: 34335479; PMCID: PMC8317220.
Lombardo G, Enache D, Gianotti L, Schatzberg AF, Young AH, Pariante CM, Mondelli V. Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis. Psychoneuroendocrinology. 2019 Dec;110:104420. doi: 10.1016/j.psyneuen.2019.104420. Epub 2019 Aug 23. PMID: 31499391.
McClung CA. How might circadian rhythms control mood? Let me count the ways.. Biol Psychiatry. 2013 Aug 15;74(4):242-9. doi: 10.1016/j.biopsych.2013.02.019. Epub 2013 Apr 1. PMID: 23558300; PMCID: PMC3725187.
Moebus S, Hanisch J, Bramlage P, Lösch C, Hauner H, Wasem J, Jöckel KH. Regional differences in the prevalence of the metabolic syndrome in primary care practices in Germany. Dtsch Arztebl Int. 2008 Mar;105(12):207-13. doi: 10.3238/artzebl.2008.0207. Epub 2008 Mar 21. PMID: 19629210; PMCID: PMC2696781.
Mückschel M, Dippel G, Beste C. Distinguishing stimulus and response codes in theta oscillations in prefrontal areas during inhibitory control of automated responses. Hum Brain Mapp. 2017 Nov;38(11):5681-5690. doi: 10.1002/hbm.23757. Epub 2017 Aug 7. PMID: 28782869; PMCID: PMC6867003.
Musliner KL, Mortensen PB, McGrath JJ, et al. Association of Polygenic Liabilities for Major Depression, Bipolar Disorder, and Schizophrenia With Risk for Depression in the Danish Population. JAMA Psychiatry. 2019;76(5):516–525. doi:10.1001/jamapsychiatry.2018.4166
Ouyang G, Sommer W, Zhou C. A toolbox for residue iteration decomposition (RIDE)--A method for the decomposition, reconstruction, and single trial analysis of event related potentials. J Neurosci Methods. 2015 Jul 30;250:7-21. doi: 10.1016/j.jneumeth.2014.10.009. Epub 2014 Oct 23. PMID: 25455337.
Pariante CM. Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. Eur Neuropsychopharmacol. 2017 Jun;27(6):554-559. doi: 10.1016/j.euroneuro.2017.04.001. Epub 2017 May 4. PMID: 28479211.
Philipp Kanske, Janine Heissler, Sandra Schönfelder, André Bongers, Michèle Wessa, How to Regulate Emotion? Neural Networks for Reappraisal and Distraction, Cerebral Cortex, Volume 21, Issue 6, June 2011, Pages 1379–1388, https://doi.org/10.1093/cercor/bhq216
Sawyer, K.M., Zunszain, P.A., Dazzan, P. et al. Intergenerational transmission of depression: clinical observations and molecular mechanisms. Mol Psychiatry 24, 1157–1177 (2019). https://doi.org/10.1038/s41380-018-0265-4
The Network and Pathway Analysis Subgroup of the Psychiatric Genomics Consortium. Correction: Corrigendum: Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci 18, 1861 (2015). https://doi.org/10.1038/nn1215-1861c
Zhao, G., Liu, X. (2019). Neuroimmune Advance in Depressive Disorder. In: Fang, Y. (eds) Depressive Disorders: Mechanisms, Measurement and Management. Advances in Experimental Medicine and Biology, vol 1180. Springer, Singapore. https://doi.org/10.1007/978-981-32-9271-0_4